Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial

Fig. 2

Mean ASDAS and BASDAI scores over 3 years. Mean ASDAS in the (a) MRI/CRP-positive subpopulation and (b) total efficacy population and mean BASDAI in the (c) MRI/CRP-positive subpopulation and (d) total efficacy population. Observed data (closed gray symbols) and LOCF data (open black symbols) through 3 years of OLE. Dashed line represents the start of the open-label adalimumab period; n values below the x-axis are for observed data at each visit, and n values in the figure legend are for the LOCF data. ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, CRP C-reactive protein, LOCF last observation carried forward, MRI magnetic resonance imaging

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us